Del. Justices Uphold Fresenius' $4.3B Akorn Merger Drop
By Jeff Montgomery ( December 7, 2018, 11:49 AM EST) -- Delaware's Supreme Court on Friday upheld a milestone Chancery Court finding that Fresenius Kabi AG had a right to terminate a $4.3 billion deal for generic-drug developer Akorn Inc., ruling less than two days after appeal arguments that Fresenius' exit relied on defensible post-signing findings of material troubles at Akorn....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.